亚太地区基于细胞片的基因治疗市场：按技术类型、细胞片类型、来源、用途、最终用户和国家进行分析（2025 年至 2035 年）

亚太地区以细胞片为基础的基因治疗市场预计将从 2024 年的 1.708 亿美元成长到 2035 年的 8.79 亿美元，预测期内的复合年增长率为 16.06%。

全球再生医学公司正积极进军该地区，与本地先驱企业携手成为主要企业的市场驱动力。 CellSeed Inc.（日本）和J-TEC（日本组织工程株式会社）等领先主要企业拥有强大的临床开发平臺和针对眼科、食道和心臟再生的近乎上市的治疗方法。这些公司受益于日本政府对再生医学的大力支持和先进的监管体系，这促进了市场扩张和创新。

在组织工程学的进步和再生医学日益增长的需求的推动下，亚洲基于细胞片层的基因治疗市场正在稳步增长。这种创新的治疗方法结合了基因修饰和细胞片层技术，无需支架即可实现标靶组织修復，同时保留细胞外基质和细胞间黏附。中国、韩国和日本等国家在先进生物製药投资不断增加以及良好的法规环境的推动下，处于研究和商业化的前沿。

尤其是日本，凭藉其先进的再生医学法规结构，在皮肤修復、角膜修復、食道重组和心肌再生等临床应用方面取得了进展。韩国正在拓展其生物技术基础设施，同时注重精密製造和国际伙伴关係。中国也迅速适应国际标准，以促进国内创新并发展临床研发管线。

人口老化、慢性病发生率上升以及政府加大对生技研发投入等因素也在推动市场扩张。然而，复杂的製造流程、高成本以及不同地区监管体系的差异等挑战可能会阻碍市场扩张。然而，随着技术创新的不断推进、产学研合作的不断推进以及区域监管协调倡议的推进，亚太地区有望成为未来基因和细胞治疗的主要枢纽。

市场区隔:

细分一：按技术类型

• 细胞片层工程
  • 光诱导细胞片技术
  • 温度响应培养表面
  • 无支架技术
  • 逐层组装
  • 其他技术
• 基因转移方法
  • 基于病毒载体的方法（例如慢病毒、腺病毒）
  • 非病毒载体方法（例如脂质体、奈米粒子）
  • CRISPR/Cas9
  • 其他基因转移方法

细分2：按细胞片类型

• 单层细胞片
• 共培养细胞片
• 多层细胞片
• 其他的

细分3：按来源地

• 自体
• 同源
• 干细胞衍生

细分 4：按应用

• 瘤
• 眼科
• 遗传性疾病
• 心臟病学
• 其他的

细分 5：按最终用户

• 医院和诊所
• 研究和学术机构
• 生物技术和製药公司
• 其他的

细分6：按地区

• 亚太地区
  • 日本
  • 印度
  • 中国
  • 澳洲
  • 韩国
  • 其他的

本报告调查了亚太地区基于细胞片的基因治疗市场，并总结了关键趋势、市场影响因素分析、法律制度、技术和专利分析、市场规模趋势和预测、各个细分市场、地区/主要国家的详细分析、竞争格局以及主要企业的概况。

目录

执行摘要

范围和定义

第一章基于细胞片的基因治疗市场：产业展望

• 基于细胞片的基因治疗市场趋势
  • 再生医学与基因工程的新融合
• 竞争格局
  • 商业策略
  • 企业策略
• 认证核可药：利用细胞片的基因治疗
• 研发药物：基于细胞片的基因治疗
• 监管状况
  • 亚太地区
• 市场动态
  • 趋势、驱动因素、挑战和机会：评估当前和未来的影响
  • 市场驱动因素
  • 市场限制
  • 市场机会
• 市场挑战
  • 监理核准和道德问题

第二章 细胞片基因治疗市场（按地区）

• 区域摘要
• 亚太地区
  • 区域概况
  • 市场成长动力
  • 市场问题
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 其他的

第三章调查方法

This report can be delivered in 2 working days.

Introduction to Asia-Pacific (APAC) Cell Sheet-based Gene Therapy Market

The Asia-Pacific cell sheet-based gene therapy market is projected to reach $879.0 million by 2035 from $170.8 million in 2024, growing at a CAGR of 16.06% during the forecast period 2025-2035. Global regenerative medicine businesses aggressively extending their footprint and regional pioneers are major players in the APAC cell sheet-based gene therapy market. Leading companies in the field, including CellSeed Inc. (Japan) and J-TEC (Japan Tissue Engineering Co., Ltd.), have robust clinical pipelines and treatments that are ready for the market that target ocular, esophageal, and cardiac regeneration. These businesses profit from Japan's robust government backing for regenerative medicine and its innovative regulatory framework.

Temperature-responsive culture dishes are used by CellSeed Inc. to produce autologous cell sheet products, and J-TEC has created and marketed a number of autologous cell-based goods, such as skin and cartilage repair products. Scalable clinical deployment throughout Asia is supported by their integrated R&D and GMP-compliant production facilities.

In the meantime, further funding and collaborations are being made in nations like China and South Korea with the goal of commercializing gene-modified cell sheets for uncommon ocular and dermatological disorders. Through strategic partnerships between academia, government, and the commercial sector, biotech firms and institutions around the area are placing an emphasis on translational research and industrial scalability.

These advancements establish APAC as a competitive center for next-generation cell sheet-based gene treatments and demonstrate the region's expanding significance in fostering innovation for complicated epithelium and tissue regeneration therapies.

Market Introduction

The market for cell sheet-based gene therapy in Asia is expanding steadily because to advances in tissue engineering and the growing need for regenerative medicine. This novel therapeutic strategy maintains the integrity of the extracellular matrix and cell-to-cell connections while enabling targeted tissue repair without the need for scaffolds through the combination of genetic alteration and cell sheet technology. With the help of advantageous regulatory environments and rising investments in cutting-edge biologics, nations like China, South Korea, and Japan are leading the way in research and commercialization.

Clinical applications in skin healing, corneal restoration, esophagus reconstruction, and cardiac regeneration have advanced due to Japan's innovative position in regulating regenerative medicine. With a focus on precision manufacturing and global partnerships, South Korea is also growing its biotech infrastructure. Furthermore, in an effort to foster domestic innovation and develop clinical pipelines, China is quickly bringing itself into compliance with international norms.

Market expansion is also supported by aging populations, the growing burden of chronic diseases, and greater government investment for biotechnology R&D. Scalability may be hampered by issues including intricate manufacturing procedures, exorbitant expenses, and regionally disparate regulations. Notwithstanding these obstacles, ongoing technological advancements, collaborations between academia and business, and regional harmonization initiatives are establishing Asia-Pacific as a major center for gene and cell therapies of the future.

Market Segmentation

Segmentation 1: By Technology Type

• Cell sheet-based Engineering Techniques
  • Light-induced cell sheet technology
  • Temperature-Responsive Culture Surfaces
  • Scaffold-Free Techniques
  • Layer-by-Layer Assembly
  • Other Techniques
• Gene Delivery Methods
  • Viral Vector-Based (e.g., Lentivirus, Adenovirus)
  • Non-Viral Vector-Based (e.g., Liposomes, Nanoparticles)
  • CRISPR/Cas9
  • Other Gene Delivery Methods

Segmentation 2: By Cell-Sheet Type

• Monolayer Cell-sheet Type
• Co-culture Cell-sheet Type
• Multilayered Cell-sheet Type
• Others

Segmentation 3: By Source Type

• Autologous
• Allogenic
• Stem-cell Derived

Segmentation 4: By Application

• Oncology
• Ophthalmology
• Genetic Disorders
• Cardiology
• Others

Segmentation 5: By End-User

• Hospitals and Clinics
• Research and Academic Institutions
• Biotech and Pharma Companies
• Others

Segmentation 6: By Region

• Asia-Pacific
  • Japan
  • India
  • China
  • Australia
  • South Korea
  • Rest-of-Asia-Pacific

APAC Cell Sheet-Based Gene Therapy Market Trends, Drivers and Challenges

Market Trends

• Rapid growth of the cell and gene therapy sector in the

APAC region, supported by increasing clinical trials and commercial interest.

• Rising adoption of autologous therapies, especially for oncology, genetic, and regenerative applications.
• Strong innovation pipeline in countries like Japan, South Korea, and China for late-stage cell sheet therapies targeting cartilage, ocular, and skin tissues.

Market Drivers

• Growing burden of chronic, genetic, and age-related diseases is increasing demand for regenerative therapies.
• Supportive regulatory initiatives and fast-track approval mechanisms in key APAC countries are encouraging development and commercialization.
• Expanding public-private partnerships and infrastructure investments are boosting manufacturing capacity and clinical translation.

Market Challenges

• High production and operational costs for cell sheet-based therapies limit affordability and accessibility.
• Fragmented regulatory requirements across the region create hurdles for cross-border clinical and commercial integration.
• Shortage of skilled talent in advanced cell therapy manufacturing and quality control remains a key bottleneck.

Market Opportunities

• Integration of automation and AI-driven quality control to streamline production and reduce time to market.
• Expansion of contract manufacturing organizations (CMOs) and academic-industry collaborations to scale innovation.
• Increasing focus on personalized medicine and precision therapies is creating demand for novel cell-based platforms.

How can this report add value to an organization

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in APAC cell sheet-based gene therapy, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.

Regulatory and Compliance Strategy: It provides updates on evolving regulatory frameworks, approvals, and industry guidelines, ensuring organizations stay compliant and accelerate market entry for new APAC cell sheet-based gene therapy.

Investment and Business Expansion Strategy: By analyzing market trends, funding patterns, and partnership opportunities, the report assists organizations in making informed investment decisions and identifying potential M&A opportunities for business growth.

Table of Contents

Executive Summary

Scope and Definition

1 Cell sheet-based Gene Therapy Market: Industry Outlook

• 1.1 Trends in Cell Sheet-based Gene Therapy Market
  • 1.1.1 Emerging Convergence of Regenerative Medicine and Genetic Engineering
• 1.2 Competitive Landscape
  • 1.2.1 Business Strategies
    • 1.2.1.1 Product Developments
  • 1.2.2 Corporate Strategies
    • 1.2.2.1 Partnerships and Joint Ventures
• 1.3 Approved Drugs, Cell sheet-based Gene Therapy
• 1.4 Pipeline Drugs, Cell sheet-based Gene Therapy
• 1.5 Regulatory Landscape
  • 1.5.1 Asia-Pacific
    • 1.5.1.1 Japan
    • 1.5.1.2 China
    • 1.5.1.3 South Korea
• 1.6 Market Dynamics
  • 1.6.1 Trends, Drivers, Challenges, and Opportunities: Current and Future Impact Assessment
  • 1.6.2 Market Drivers
    • 1.6.2.1 Advancement in Regenerative Medicine
    • 1.6.2.2 Growing Investment in Personalized Medicine
    • 1.6.2.3 Technological Advancements in Cell Sheet Therapy
  • 1.6.3 Market Restraints
    • 1.6.3.1 Rising Cost of Development and Manufacturing
  • 1.6.4 Market Opportunities
    • 1.6.4.1 Substantial Surge in the Rise of Cell Sheet Approaches
    • 1.6.4.2 Rising Application for Localized and Minimally Invasive Treatments
• 1.7 Market Challenges
  • 1.7.1 Regulatory Approval and Ethical Issues

2 Cell Sheet-based Gene Therapy Market (by Region), Value ($million), 2023-2035

• 2.1 Regional Summary
• 2.2 Asia-Pacific
  • 2.2.1 Regional Overview
  • 2.2.2 Driving Factors for Market Growth
  • 2.2.3 Factors Challenging the Market
  • 2.2.4 Japan
  • 2.2.5 China
  • 2.2.6 India
  • 2.2.7 Australia
  • 2.2.8 South Korea
  • 2.2.9 Rest-of-Asia-Pacific

3 Research Methodology

• 3.1 Data Sources
  • 3.1.1 Primary Data Sources
  • 3.1.2 Secondary Data Sources
  • 3.1.3 Inclusion and Exclusion
  • 3.1.4 Data Triangulation
• 3.2 Market Estimation and Forecast

List of Figures

• Figure 1: Asia-Pacific Cell Sheet-based Gene Therapy Market (by Scenario), $Million, 2024, 2028, and 2035
• Figure 2: Asia-Pacific Cell Sheet-based Gene Therapy Market, 2024-2035
• Figure 3: Asia-Pacific Cell Sheet-based Gene Therapy Market Snapshot
• Figure 4: Asia-Pacific Cell Sheet-based Gene Therapy Market (by Technology Type), $Million, 2024, 2028, and 2035
• Figure 5: Asia-Pacific Cell Sheet-based Gene Therapy Market (by Cell-Sheet Type), $Million, 2024, 2028, and 2035
• Figure 6: Asia-Pacific Cell Sheet-based Gene Therapy Market (by Source Type), $Million, 2024, 2028, and 2035
• Figure 7: Asia-Pacific Cell Sheet-based Gene Therapy Market (by Application Type), $Million, 2024, 2028, and 2035
• Figure 8: Asia-Pacific Cell Sheet-based Gene Therapy Market (by End User), $Million, 2024, 2028, and 2035
• Figure 9: Japan Cell Sheet-based Gene Therapy Market, $Million, 2023-2035
• Figure 10: China Cell Sheet-based Gene Therapy Market, $Million, 2023-2035
• Figure 11: India Cell Sheet-based Gene Therapy Market, $Million, 2023-2035
• Figure 12: Australia Cell Sheet-based Gene Therapy Market, $Million, 2023-2035
• Figure 13: South Korea Cell Sheet-based Gene Therapy Market, $Million, 2023-2035
• Figure 14: Rest of Asia-Pacific Cell Sheet-based Gene Therapy Market, $Million, 2023-2035
• Figure 15: Inclusion and Exclusion Criteria for Cell Sheet-based Gene Therapy Market
• Figure 16: Data Triangulation
• Figure 17: Top-Down and Bottom-Up Approach
• Figure 18: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Approved Drugs in Cell-Sheet based Gene Therapy Market
• Table 3: Pipeline Drugs in Cell-Sheet based Gene Therapy Market
• Table 4: Cell Sheet-based Gene Therapy Market (by Region), $Million, 2023-2035
• Table 5: Asia-Pacific Cell Sheet-based Gene Therapy Market (by Technology Type), $Million, 2023-2035
• Table 6: Asia-Pacific Cell Sheet-based Gene Therapy Market (by Cell sheet-based Engineering Techniques Type), $Million, 2023-2035
• Table 7: Asia-Pacific Cell Sheet-based Gene Therapy Market (by Gene Delivery Methods), $Million, 2023-2035
• Table 8: Asia-Pacific Cell Sheet-based Gene Therapy Market (by Cell-sheet Type), $Million, 2023-2035
• Table 9: Asia-Pacific Cell Sheet-based Gene Therapy Market (by Source Type), $Million, 2023-2035
• Table 10: Asia-Pacific Cell Sheet-based Gene Therapy Market (by Application Type), $Million, 2023-2035
• Table 11: Asia-Pacific Cell Sheet-based Gene Therapy Market (by End User), $Million, 2023-2035